Dimensional Fund Advisors LP Sells 16,619 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Dimensional Fund Advisors LP lowered its holdings in Blueprint Medicines Co. (NASDAQ:BPMC) by 34.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 31,979 shares of the biotechnology company’s stock after selling 16,619 shares during the period. Dimensional Fund Advisors LP owned about 0.05% of Blueprint Medicines worth $3,447,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Triad Wealth Partners LLC purchased a new stake in shares of Blueprint Medicines in the second quarter worth about $27,000. Covestor Ltd boosted its stake in shares of Blueprint Medicines by 9,700.0% in the 1st quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 291 shares in the last quarter. Headlands Technologies LLC grew its holdings in shares of Blueprint Medicines by 105.2% during the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 342 shares during the last quarter. Natixis bought a new stake in Blueprint Medicines in the first quarter worth $73,000. Finally, CWM LLC grew its stake in shares of Blueprint Medicines by 114.6% during the second quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 590 shares during the last quarter.

Blueprint Medicines Stock Down 0.7 %

BPMC opened at $86.97 on Friday. Blueprint Medicines Co. has a twelve month low of $43.89 and a twelve month high of $121.90. The company has a quick ratio of 3.65, a current ratio of 3.71 and a debt-to-equity ratio of 1.06. The firm has a 50 day moving average price of $91.10 and a 200-day moving average price of $98.95. The stock has a market capitalization of $5.45 billion, a price-to-earnings ratio of -18.08 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.49. The company had revenue of $138.20 million during the quarter, compared to analysts’ expectations of $104.02 million. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. Blueprint Medicines’s revenue for the quarter was up 139.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.19) earnings per share. Equities research analysts forecast that Blueprint Medicines Co. will post -3.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BPMC. Guggenheim increased their target price on shares of Blueprint Medicines from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Morgan Stanley upped their price objective on shares of Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a report on Friday, July 12th. Robert W. Baird lifted their target price on shares of Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Baird R W upgraded shares of Blueprint Medicines to a “strong-buy” rating in a report on Friday, August 2nd. Finally, Barclays upped their target price on Blueprint Medicines from $75.00 to $105.00 and gave the stock an “equal weight” rating in a report on Monday, July 29th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $120.00.

Insider Activity

In other news, insider Fouad Namouni sold 3,633 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the sale, the insider now directly owns 69,070 shares of the company’s stock, valued at $6,169,332.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Fouad Namouni sold 3,633 shares of the stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the sale, the insider now owns 69,070 shares in the company, valued at approximately $6,169,332.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Philina Lee sold 41,913 shares of the firm’s stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the sale, the insider now directly owns 34,729 shares of the company’s stock, valued at approximately $3,236,395.51. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.21% of the company’s stock.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.